Symbols / CLLS Stock $3.98 +0.51% Cellectis S.A.

Healthcare • Biotechnology • France • NGM
CLLS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Andre Choulika Ph.D.
Exch · Country NGM · France
Market Cap 400.43M
Enterprise Value 397.46M
Income -67.23M
Sales 75.11M
FCF (ttm) -53.55M
Book/sh 0.60
Cash/sh 0.35
Employees 224
Insider 10d —
IPO Mar 24, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.42
PEG —
P/S 5.33
P/B 6.68
P/C —
EV/EBITDA -12.00
EV/Sales 5.29
Quick Ratio 0.35
Current Ratio 1.52
Debt/Eq 53.74
LT Debt/Eq —
EPS (ttm) -0.67
EPS next Y -0.62
EPS Growth —
Revenue Growth -37.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-11
Earnings (prior) 2026-05-11
ROA -8.43%
ROE -76.34%
ROIC —
Gross Margin 100.00%
Oper. Margin -3.33%
Profit Margin -89.51%
Shs Outstand 72.61M
Shs Float 64.64M
Insider Own 0.00%
Instit Own 16.91%
Short Float 0.66%
Short Ratio 9.66
Short Interest 364.18K
52W High 5.48
vs 52W High -27.37%
52W Low 1.33
vs 52W Low 199.92%
Beta —
Impl. Vol. 25.00%
Rel Volume 0.74
Avg Volume 39.31K
Volume 29.23K
Target (mean) $7.25
Tgt Median $7.50
Tgt Low $4.00
Tgt High $10.00
# Analysts 4
Recom Buy
Prev Close $3.96
Price $3.98
Change 0.51%
About

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.25
Mean price target
2. Current target
$3.98
Latest analyst target
3. DCF / Fair value
$-13.28
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.98
Low
$4.00
High
$10.00
Mean
$7.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-14 reit Citizens Market Outperform → Market Outperform $8
2025-12-23 init Clear Street — → Buy $9
2025-10-17 main Barclays Overweight → Overweight $8
2025-05-13 main Barclays Overweight → Overweight $4
2024-11-05 main Barclays Overweight → Overweight $5
2024-06-12 main Oppenheimer Outperform → Outperform $10
2024-05-31 reit JMP Securities Market Outperform → Market Outperform $6
2023-11-01 reit JMP Securities Market Outperform → Market Outperform $6
2023-08-08 reit Oppenheimer Outperform → Outperform $11
2023-08-07 reit JMP Securities Market Outperform → Market Outperform $6
2023-04-05 main Citigroup — → Buy $16
2023-03-13 main Oppenheimer — → Outperform $13
2023-03-13 reit JMP Securities — → Market Outperform $6
2023-01-19 main JMP Securities — → Market Outperform $6
2022-05-24 main Goldman Sachs — → Sell $2
2022-05-18 up Baird Neutral → Outperform —
2022-05-13 main Barclays — → Overweight $7
2022-01-06 down Wells Fargo Overweight → Equal-Weight $16
2021-11-30 init JMP Securities — → Market Outperform $20
2021-10-08 down Baird Outperform → Neutral $10
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
72.95
+75.76%
41.51
+5397.48%
0.76
-96.06%
19.17
Operating Revenue
72.95
+75.76%
41.51
+5397.48%
0.76
-96.06%
19.17
Cost Of Revenue
9.80
+6.70%
9.18
+23.76%
7.42
-12.55%
8.48
Reconciled Cost Of Revenue
9.80
+6.70%
9.18
+23.76%
7.42
-12.55%
8.48
Gross Profit
63.15
+95.37%
32.32
+585.05%
-6.66
-162.36%
10.69
Operating Expense
96.23
+4.73%
91.88
+1.37%
90.64
-9.68%
100.35
Research And Development
93.52
+3.29%
90.54
+3.30%
87.65
-10.11%
97.50
Selling General And Administration
8.60
+2.09%
8.42
+3.71%
8.12
-8.72%
8.89
Selling And Marketing Expense
—
—
—
3.11
General And Administrative Expense
8.60
+2.09%
8.42
+3.71%
8.12
-8.72%
8.89
Salaries And Wages
7.68
+2.51%
7.49
+1.52%
7.38
-3.82%
7.67
Other Gand A
0.92
-1.29%
0.93
+25.61%
0.74
-39.56%
1.22
Other Operating Expenses
-7.28
+14.94%
-8.56
-19.94%
-7.14
+9.99%
-7.93
Total Expenses
106.03
+4.91%
101.06
+3.06%
98.06
-9.90%
108.84
Operating Income
-33.08
+44.46%
-59.55
+38.80%
-97.30
-8.52%
-89.67
Total Operating Income As Reported
-33.08
+44.46%
-59.55
+38.79%
-97.30
-8.52%
-89.67
EBITDA
-39.85
-321.13%
-9.46
+89.79%
-92.64
-21.29%
-76.38
Normalized EBITDA
-3.52
+87.63%
-28.43
+62.73%
-76.28
+7.46%
-82.44
Reconciled Depreciation
20.06
+1.09%
19.85
+7.14%
18.52
+0.48%
18.43
EBIT
-59.91
-104.41%
-29.31
+73.63%
-111.16
-17.24%
-94.81
Total Unusual Items
-36.33
-291.54%
18.97
+216.00%
-16.35
-369.83%
6.06
Total Unusual Items Excluding Goodwill
-36.33
-291.54%
18.97
+216.00%
-16.35
-369.83%
6.06
Net Income
-67.59
-83.87%
-36.76
+63.62%
-101.06
+4.79%
-106.14
Pretax Income
-68.02
-85.02%
-36.76
+68.44%
-116.47
-18.12%
-98.60
Net Non Operating Interest Income Expense
1.39
-63.63%
3.83
+236.02%
-2.81
+81.25%
-14.99
Interest Expense Non Operating
8.11
+8.77%
7.45
+40.44%
5.31
+40.14%
3.79
Net Interest Income
1.39
-63.63%
3.83
+236.02%
-2.81
+81.25%
-14.99
Interest Expense
8.11
+8.77%
7.45
+40.44%
5.31
+40.14%
3.79
Interest Income Non Operating
9.50
-15.78%
11.28
+212.06%
3.61
+222.68%
1.12
Interest Income
9.50
-15.78%
11.28
+212.06%
3.61
+222.68%
1.12
Other Income Expense
-36.33
-291.54%
18.97
+216.00%
-16.35
-369.83%
6.06
Gain On Sale Of Security
-36.33
-291.54%
18.97
+216.00%
-16.35
-369.83%
6.06
Tax Provision
-0.42
0.00
-100.00%
0.37
+326.44%
0.09
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.23
0.00
+100.00%
-4.09
-369.83%
1.51
Net Income Including Noncontrolling Interests
-67.59
-83.87%
-36.76
+66.10%
-108.44
+4.90%
-114.03
Net Income From Continuing Operation Net Minority Interest
-67.59
-83.87%
-36.76
+66.41%
-109.45
-20.55%
-90.79
Net Income From Continuing And Discontinued Operation
-67.59
-83.87%
-36.76
+63.62%
-101.06
+4.79%
-106.14
Net Income Continuous Operations
-67.59
-83.87%
-36.76
+68.54%
-116.83
-18.39%
-98.69
Net Income Discontinuous Operations
0.00
0.00
-100.00%
8.39
+154.69%
-15.35
Minority Interests
0.00
0.00
-100.00%
7.38
-6.46%
7.89
Normalized Income
-31.49
+43.50%
-55.73
+42.66%
-97.19
-1.94%
-95.34
Net Income Common Stockholders
-67.59
-83.87%
-36.76
+63.62%
-101.06
+4.79%
-106.14
Diluted EPS
-0.67
-63.41%
-0.41
+76.84%
-1.77
+24.03%
-2.33
Basic EPS
-0.67
-63.41%
-0.41
+76.84%
-1.77
+24.03%
-2.33
Basic Average Shares
100.28
+10.72%
90.57
+58.85%
57.01
+25.16%
45.55
Diluted Average Shares
100.28
+10.72%
90.57
+58.85%
57.01
+25.16%
45.55
Diluted NI Availto Com Stockholders
-67.59
-83.87%
-36.76
+63.62%
-101.06
+4.79%
-106.14
Depreciation Amortization Depletion Income Statement
1.40
-5.80%
1.48
-26.29%
2.01
+6.62%
1.89
Depreciation And Amortization In Income Statement
1.40
-5.80%
1.48
-26.29%
2.01
+6.62%
1.89
Other Taxes
—
—
-6.58
-0.55%
-6.55
Total Other Finance Cost
—
—
1.12
-90.92%
12.33
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
324.72
-15.34%
383.54
+14.74%
334.27
+27.97%
261.22
Current Assets
236.25
-17.70%
287.07
+23.20%
233.01
+62.02%
143.81
Cash Cash Equivalents And Short Term Investments
208.66
-19.84%
260.31
+27.72%
203.81
+108.62%
97.70
Cash And Cash Equivalents
61.53
-57.05%
143.25
+4.79%
136.71
+52.25%
89.79
Cash Equivalents
15.62
-85.85%
110.34
+100.61%
55.00
+121.97%
24.78
Cash Financial
45.91
+39.50%
32.91
-59.72%
81.71
+25.68%
65.01
Other Short Term Investments
147.13
+25.69%
117.06
+74.43%
67.11
+748.70%
7.91
Receivables
25.32
+9.90%
23.04
-0.40%
23.13
+31.61%
17.57
Accounts Receivable
14.40
+114.45%
6.71
+1079.96%
0.57
-26.30%
0.77
Gross Accounts Receivable
14.40
+114.45%
6.71
+1079.96%
0.57
-26.30%
0.77
Allowance For Doubtful Accounts Receivable
0.00
0.00
0.00
0.00
Other Receivables
0.09
—
—
—
Taxes Receivable
10.83
-33.65%
16.32
-27.65%
22.56
+34.28%
16.80
Inventory
—
—
—
0.00
Prepaid Assets
1.93
-43.58%
3.43
-40.03%
5.72
-8.29%
6.23
Current Deferred Assets
—
—
—
0.54
Assets Held For Sale Current
—
—
0.00
-100.00%
21.77
Other Current Assets
0.33
+10.74%
0.30
-13.62%
0.34
-35.87%
0.54
Total Non Current Assets
88.48
-8.29%
96.48
-4.73%
101.27
-13.75%
117.41
Net PPE
62.45
-17.69%
75.86
-18.20%
92.74
-14.05%
107.90
Gross PPE
176.04
+5.26%
167.24
-0.54%
168.16
+2.77%
163.62
Accumulated Depreciation
-113.59
-24.31%
-91.38
-21.17%
-75.42
-35.34%
-55.72
Properties
0.00
0.00
0.00
0.00
Land And Improvements
20.92
+15.33%
18.14
-2.18%
18.54
+4.52%
17.74
Buildings And Improvements
53.75
+5.57%
50.91
-1.83%
51.86
+4.94%
49.42
Machinery Furniture Equipment
5.17
+1.29%
5.10
+2.55%
4.97
+1.20%
4.91
Construction In Progress
1.36
+632.80%
0.19
-85.37%
1.27
+33.51%
0.95
Other Properties
94.84
+2.08%
92.91
+1.53%
91.50
+1.01%
90.59
Goodwill And Other Intangible Assets
0.54
-52.02%
1.11
+65.92%
0.67
-6.41%
0.72
Other Intangible Assets
0.54
-52.02%
1.11
+65.92%
0.67
-6.41%
0.72
Investments And Advances
5.09
-32.35%
7.52
-4.23%
7.85
-10.67%
8.79
Non Current Deferred Assets
0.38
+0.00%
0.38
—
—
Non Current Deferred Taxes Assets
0.38
+0.00%
0.38
—
—
Other Non Current Assets
20.02
+72.70%
11.60
+1159600.00%
-0.00
—
Total Liabilities Net Minority Interest
248.82
-1.46%
252.51
+1.18%
249.57
+84.49%
135.28
Current Liabilities
145.75
-12.34%
166.27
+7.17%
155.14
+146.28%
62.99
Payables And Accrued Expenses
28.12
+2.23%
27.51
-3.26%
28.44
-16.20%
33.94
Payables
17.36
-7.08%
18.68
-2.04%
19.07
-22.21%
24.51
Accounts Payable
17.28
-7.43%
18.66
-2.12%
19.07
-11.13%
21.46
Current Accrued Expenses
10.77
+21.93%
8.83
-5.74%
9.37
-0.56%
9.42
Employee Benefits
1.33
+19.19%
1.11
-49.32%
2.20
-7.95%
2.39
Total Tax Payable
0.08
+400.00%
0.02
0.00
-100.00%
3.06
Current Debt And Capital Lease Obligation
11.79
-10.85%
13.23
-3.21%
13.66
+6.38%
12.84
Current Debt
4.09
-15.51%
4.84
-6.22%
5.16
+3.82%
4.97
Other Current Borrowings
4.09
-15.51%
4.84
-6.22%
5.16
+3.82%
4.97
Current Capital Lease Obligation
7.70
-8.16%
8.38
-1.38%
8.50
+8.00%
7.87
Current Deferred Liabilities
96.80
-13.69%
112.16
+1.66%
110.33
+186891.53%
0.06
Current Deferred Revenue
96.80
-13.69%
112.16
+1.66%
110.33
+186891.53%
0.06
Other Current Liabilities
7.87
-37.30%
12.54
+1182.62%
0.98
-93.76%
15.68
Total Non Current Liabilities Net Minority Interest
103.07
+19.51%
86.24
-8.67%
94.43
+30.65%
72.28
Long Term Debt And Capital Lease Obligation
78.94
+0.90%
78.23
+9.59%
71.39
+13.45%
62.93
Long Term Debt
51.22
+16.43%
43.99
+54.65%
28.44
+109.62%
13.57
Long Term Capital Lease Obligation
27.73
-19.04%
34.24
-20.26%
42.95
-12.99%
49.36
Long Term Provisions
—
—
2.20
-7.95%
2.39
Non Current Pension And Other Postretirement Benefit Plans
1.33
+19.19%
1.11
-49.32%
2.20
-7.95%
2.39
Non Current Deferred Liabilities
—
0.00
-100.00%
0.16
—
Non Current Deferred Taxes Liabilities
—
0.00
-100.00%
0.16
—
Other Non Current Liabilities
0.74
-16.33%
0.88
-93.15%
12.88
+85.04%
6.96
Stockholders Equity
75.90
-42.07%
131.03
+54.71%
84.69
-28.21%
117.97
Common Stock Equity
75.90
-42.07%
131.03
+54.71%
84.69
-28.21%
117.97
Capital Stock
5.90
+0.24%
5.89
+34.91%
4.37
+47.72%
2.96
Common Stock
5.90
+0.24%
5.89
+34.91%
4.37
+47.72%
2.96
Share Issued
100.34
+39.18%
72.09
+0.48%
71.75
+57.09%
45.68
Ordinary Shares Number
100.34
+39.18%
72.09
+0.48%
71.75
+57.09%
45.68
Additional Paid In Capital
437.44
-11.50%
494.29
-5.45%
522.78
-10.35%
583.12
Retained Earnings
-334.13
-1.37%
-329.61
+18.77%
-405.77
+7.68%
-439.50
Gains Losses Not Affecting Retained Earnings
-33.32
+15.73%
-39.54
-7.76%
-36.69
-28.26%
-28.61
Minority Interest
—
—
0.00
-100.00%
7.97
Total Equity Gross Minority Interest
75.90
-42.07%
131.03
+54.71%
84.69
-32.75%
125.94
Total Capitalization
127.12
-27.37%
175.02
+54.70%
113.14
-13.99%
131.54
Working Capital
90.49
-25.09%
120.80
+55.15%
77.86
-3.65%
80.81
Invested Capital
131.21
-27.05%
179.86
+52.04%
118.30
-13.34%
136.51
Total Debt
90.73
-0.80%
91.46
+7.53%
85.06
+12.25%
75.77
Capital Lease Obligations
35.43
-16.90%
42.63
-17.14%
51.45
-10.10%
57.23
Net Tangible Assets
75.37
-41.99%
129.92
+54.62%
84.02
-28.34%
117.25
Tangible Book Value
75.37
-41.99%
129.92
+54.62%
84.02
-28.34%
117.25
Available For Sale Securities
5.09
+71.60%
2.96
-7.26%
3.20
-21.55%
4.08
Current Provisions
1.17
+41.18%
0.83
-52.41%
1.74
+264.78%
0.48
Derivative Product Liabilities
22.06
+267.04%
6.01
-22.92%
7.80
0.00
Financial Assets Designatedas Fair Value Through Profitor Loss Total
0.00
-100.00%
4.56
-2.15%
4.66
-1.27%
4.72
Foreign Currency Translation Adjustments
-33.32
+15.73%
-39.54
-7.76%
-36.69
-28.26%
-28.61
Investmentin Financial Assets
5.09
-32.35%
7.52
-4.23%
7.85
-10.67%
8.79
Other Equity Interest
—
—
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-39.40
-271.39%
22.99
+192.90%
-24.75
+71.70%
-87.44
Cash Flow From Continuing Operating Activities
-39.40
-271.39%
22.99
+208.94%
-21.10
+69.35%
-68.84
Cash From Discontinued Operating Activities
0.00
0.00
+100.00%
-3.64
+80.41%
-18.60
Net Income From Continuing Operations
-67.59
-83.87%
-36.76
+68.54%
-116.83
-18.39%
-98.69
Depreciation Amortization Depletion
20.06
+1.09%
19.85
+7.14%
18.52
+0.48%
18.43
Depreciation And Amortization
20.06
+1.09%
19.85
+7.14%
18.52
+0.48%
18.43
Other Non Cash Items
34.94
+268.10%
-20.79
-217.03%
17.76
+105.88%
8.63
Stock Based Compensation
6.11
+92.93%
3.17
-39.48%
5.23
-13.40%
6.04
Provisionand Write Offof Assets
0.33
+117.81%
-1.88
-238.68%
1.35
+400.74%
0.27
Deferred Tax
-0.42
+21.52%
-0.54
-245.28%
0.37
+326.44%
0.09
Deferred Income Tax
-0.42
+21.52%
-0.54
-245.28%
0.37
+326.44%
0.09
Operating Gains Losses
0.34
+218.47%
-0.29
-3687.50%
0.01
-99.16%
0.95
Net Foreign Currency Exchange Gain Loss
0.34
+210.06%
-0.31
-3950.00%
0.01
+101.20%
-0.66
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
-41.59
-177.50%
53.66
+9.84%
48.86
+953.71%
-5.72
Change In Receivables
-9.45
-120.61%
45.86
+1250.58%
-3.99
+55.68%
-8.99
Changes In Account Receivables
-5.02
-109.54%
52.60
+2235.52%
2.25
+170.66%
-3.19
Change In Inventory
—
—
0.00
0.00
Change In Payables And Accrued Expense
-3.26
-258.59%
2.06
+132.59%
-6.30
-294.18%
3.25
Change In Payable
-3.26
-258.59%
2.06
+132.59%
-6.30
-294.18%
3.25
Change In Account Payable
-3.26
-258.59%
2.06
+132.59%
-6.30
-294.18%
3.25
Change In Other Working Capital
-28.88
-602.49%
5.75
-90.28%
59.15
+257069.57%
0.02
Investing Cash Flow
-29.48
+71.32%
-102.81
-562.85%
-15.51
-461.75%
-2.76
Cash Flow From Continuing Investing Activities
-29.48
+71.32%
-102.81
-559.49%
-15.59
-573.39%
-2.31
Cash From Discontinued Investing Activities
0.00
0.00
-100.00%
0.08
+117.71%
-0.45
Net PPE Purchase And Sale
-2.36
+8.63%
-2.58
-140.73%
-1.07
+55.86%
-2.43
Purchase Of PPE
-2.36
+8.63%
-2.58
-140.73%
-1.07
+55.86%
-2.43
Sale Of PPE
—
—
—
—
Capital Expenditure
-3.53
+8.07%
-3.84
-258.15%
-1.07
+56.04%
-2.44
Net Investment Purchase And Sale
-25.95
+73.78%
-98.96
-668.71%
-12.87
-10317.46%
0.13
Purchase Of Investment
-159.78
+1.84%
-162.77
-1118.06%
-13.36
0.00
Sale Of Investment
133.83
+109.74%
63.81
+12948.26%
0.49
+288.10%
0.13
Net Intangibles Purchase And Sale
-1.17
+6.90%
-1.26
0.00
+100.00%
-0.01
Purchase Of Intangibles
-1.17
+6.90%
-1.26
0.00
+100.00%
-0.01
Net Other Investing Changes
-0.00
+0.00%
-0.00
+99.94%
-1.64
—
Financing Cash Flow
-16.76
-118.81%
89.11
+7.54%
82.86
+7137.12%
1.15
Cash Flow From Continuing Financing Activities
-16.76
-118.81%
89.11
+9.90%
81.08
+1180.40%
-7.50
Net Issuance Payments Of Debt
-16.19
-326.86%
7.14
-47.05%
13.48
+304.12%
-6.60
Issuance Of Debt
0.00
-100.00%
23.20
-21.81%
29.67
+416.02%
5.75
Repayment Of Debt
-16.19
-0.81%
-16.06
+0.79%
-16.19
-31.06%
-12.35
Long Term Debt Issuance
0.00
-100.00%
23.20
-21.81%
29.67
+416.02%
5.75
Long Term Debt Payments
-16.19
-0.81%
-16.06
+0.79%
-16.19
-31.06%
-12.35
Net Long Term Debt Issuance
-16.19
-326.86%
7.14
-47.05%
13.48
+304.12%
-6.60
Net Common Stock Issuance
0.04
-99.95%
82.82
+21.91%
67.94
+12039.54%
-0.57
Common Stock Payments
—
—
—
-0.57
Cash Dividends Paid
0.00
0.00
0.00
0.00
Repurchase Of Capital Stock
—
—
—
-0.57
Proceeds From Stock Option Exercised
—
—
0.00
0.00
Net Other Financing Charges
—
—
0.00
—
Changes In Cash
-85.65
-1021.42%
9.29
-78.18%
42.61
+147.84%
-89.06
Effect Of Exchange Rate Changes
3.93
+242.73%
-2.75
-411.31%
0.88
+126.31%
-3.36
Beginning Cash Position
143.25
+4.79%
136.71
+46.66%
93.22
-49.79%
185.64
End Cash Position
61.53
-57.05%
143.25
+4.79%
136.71
+46.66%
93.22
Free Cash Flow
-42.93
-324.25%
19.15
+174.15%
-25.82
+71.28%
-89.89
Common Stock Issuance
0.04
-99.95%
82.82
+21.91%
67.94
—
Interest Paid CFF
-0.61
+27.74%
-0.85
-154.35%
-0.33
-0.30%
-0.33
Interest Paid CFO
—
—
—
1.16
Interest Received CFO
8.43
+28.51%
6.56
+80.81%
3.63
+213.21%
1.16
Issuance Of Capital Stock
0.04
-99.95%
82.82
+21.91%
67.94
—
Taxes Refund Paid
-0.01
—
—
—
Cash From Discontinued Financing Activities
0.00
0.00
-100.00%
1.78
-79.41%
8.65
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category